Large-vessel vasculitis (LVV) manifests as inflammation of the aorta and its major branches
and is the most common primary vasculitis in adults. LVV comprises two distinct conditions …

Systemic vasculitides are multisystem blood vessel disorders, which are defined by the size
of the vessel predominantly affected, namely small, medium, or large vessels. The term …

Abstract Aim The “2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic
Disease” provides recommendations to guide clinicians in the diagnosis, genetic evaluation …

Objective To provide evidence‐based recommendations and expert guidance for the
management of giant cell arteritis (GCA) and Takayasu arteritis (TAK) as exemplars of large …

Objective To investigate the efficacy and safety of the interleukin-6 receptor antibody
tocilizumab in patients with Takayasu arteritis (TAK). Methods Patients with TAK who had …

The pharmacotherapy of Takayasu arteritis (TAK) with disease-modifying anti-rheumatic
drugs (DMARDs) is an evolving area. A systematic review of Scopus, Web of Science …

Takayasu arteritis is an idiopathic granulomatous vasculitis of the aorta and its main
branches and it constitutes one of the more common vasculitides in children. Inflammation …

Objective To compare the efficacy of abatacept to that of placebo for the treatment of
Takayasu arteritis (TAK). Methods In this multicenter trial, patients with newly diagnosed or …

Although outcomes in Takayasu arteritis (TAK) are improving, diagnosis is typically delayed
and significant arterial injury accrues. While wider use of non-invasive imaging is impacting …

Tocilizumab (TCZ) is the first humanized anti-interleukin-6 (IL-6) receptor monoclonal
antibody approved for the treatment of patients with rheumatoid arthritis (RA), Castleman's …